Provided by Tiger Trade Technology Pte. Ltd.

Immuneering Corp

4.61
-0.1700-3.56%
Post-market: 4.630.0200+0.43%19:51 EDT
Volume:1.17M
Turnover:5.41M
Market Cap:297.67M
PE:-4.71
High:4.81
Open:4.74
Low:4.54
Close:4.78
52wk High:10.08
52wk Low:3.86
Shares:64.57M
Float Shares:49.21M
Volume Ratio:1.63
T/O Rate:2.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9796
EPS(LYR):-1.2729
ROE:-52.15%
ROA:-32.77%
PB:1.56
PE(LYR):-3.62

Loading ...

Immuneering to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 04

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)

TIPRANKS
·
Aug 27

Immuneering Enrolls Phase 3 MAPKeeper 301 Trial of Atebimetinib Combo in First-Line Metastatic Pancreatic Cancer

Reuters
·
Aug 27

aTyr Pharma Q2 Net Loss Narrows

Reuters
·
Aug 08

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 07

HC Wainwright Initiates Immuneering at Buy With $14 Price Target

MT Newswires Live
·
Aug 06

Immuneering Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 06

Immuneering Corporation : H.c. Wainwright Initiates Coverage with Buy Rating

THOMSON REUTERS
·
Aug 06

Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income

Reuters
·
Aug 06

Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge

Reuters
·
Aug 06

Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments

Reuters
·
Aug 06

Black Diamond Therapeutics Q2 Net Loss Narrows Year over Year

Reuters
·
Aug 06

Immuneering Expects Cash Runway to Fund Operations into 2029

Reuters
·
Aug 05

Immuneering Q2 EPS $(0.27), Inline

Benzinga Earnings
·
Aug 05

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
Aug 05

Immuneering publishes preclinical data on atebimetinib in Cancer Research

TIPRANKS
·
Jul 22

Immuneering Flags New Press Release on Atebimetinib Preclinical Study Publication in Cancer Research

Reuters
·
Jul 22

Immuneering Corp : Needham Raises Target Price to $18 from $11

THOMSON REUTERS
·
Jul 20

Immuneering is Maintained at Buy by Needham

Dow Jones
·
Jul 20

Immuneering Corporation Announces Grants of Inducement Awards

GlobeNewswire
·
Jul 18